vs
Side-by-side financial comparison of Ouster, Inc. (OUST) and Syndax Pharmaceuticals Inc (SNDX). Click either name above to swap in a different company.
Syndax Pharmaceuticals Inc is the larger business by last-quarter revenue ($68.5M vs $48.6M, roughly 1.4× Ouster, Inc.). Ouster, Inc. runs the higher net margin — 8.2% vs -99.3%, a 107.5% gap on every dollar of revenue. On growth, Syndax Pharmaceuticals Inc posted the faster year-over-year revenue change (791.7% vs 48.9%).
Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.
Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies for patients with hard-to-treat cancers. Its pipeline includes targeted and immunotherapy candidates addressing unmet medical needs, primarily serving global oncology healthcare stakeholders and patient populations.
OUST vs SNDX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $48.6M | $68.5M |
| Net Profit | $4.0M | $-68.0M |
| Gross Margin | 42.9% | — |
| Operating Margin | 17.6% | -91.3% |
| Net Margin | 8.2% | -99.3% |
| Revenue YoY | 48.9% | 791.7% |
| Net Profit YoY | — | 27.8% |
| EPS (diluted) | $0.06 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $48.6M | — | ||
| Q4 25 | $62.2M | $68.5M | ||
| Q3 25 | $39.5M | $45.9M | ||
| Q2 25 | $35.0M | $38.0M | ||
| Q1 25 | $32.6M | $20.0M | ||
| Q4 24 | $30.1M | — | ||
| Q3 24 | $28.1M | $12.5M | ||
| Q2 24 | $27.0M | — |
| Q1 26 | $4.0M | — | ||
| Q4 25 | — | $-68.0M | ||
| Q3 25 | $-21.7M | $-60.7M | ||
| Q2 25 | $-20.6M | $-71.8M | ||
| Q1 25 | $-22.0M | $-84.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-25.6M | $-84.1M | ||
| Q2 24 | $-23.9M | — |
| Q1 26 | 42.9% | — | ||
| Q4 25 | 60.2% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 45.2% | — | ||
| Q1 25 | 41.3% | — | ||
| Q4 24 | 43.8% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 33.7% | — |
| Q1 26 | 17.6% | — | ||
| Q4 25 | 1.5% | -91.3% | ||
| Q3 25 | -61.4% | -125.2% | ||
| Q2 25 | -76.5% | -182.7% | ||
| Q1 25 | -73.0% | -417.9% | ||
| Q4 24 | -85.1% | — | ||
| Q3 24 | -98.0% | -716.6% | ||
| Q2 24 | -93.6% | — |
| Q1 26 | 8.2% | — | ||
| Q4 25 | — | -99.3% | ||
| Q3 25 | -55.0% | -132.4% | ||
| Q2 25 | -58.8% | -189.3% | ||
| Q1 25 | -67.5% | -423.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | -91.1% | -673.0% | ||
| Q2 24 | -88.4% | — |
| Q1 26 | $0.06 | — | ||
| Q4 25 | $0.10 | $-0.78 | ||
| Q3 25 | $-0.37 | $-0.70 | ||
| Q2 25 | $-0.38 | $-0.83 | ||
| Q1 25 | $-0.42 | $-0.98 | ||
| Q4 24 | $-0.46 | — | ||
| Q3 24 | $-0.54 | $-0.98 | ||
| Q2 24 | $-0.53 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $173.1M | $394.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $275.6M | $64.6M |
| Total Assets | $381.5M | $529.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $173.1M | — | ||
| Q4 25 | $208.6M | $394.1M | ||
| Q3 25 | $244.5M | $436.0M | ||
| Q2 25 | $226.5M | $455.2M | ||
| Q1 25 | $168.2M | $512.2M | ||
| Q4 24 | $172.0M | — | ||
| Q3 24 | $151.4M | $389.6M | ||
| Q2 24 | $184.2M | — |
| Q1 26 | $275.6M | — | ||
| Q4 25 | $261.7M | $64.6M | ||
| Q3 25 | $247.4M | $115.4M | ||
| Q2 25 | $221.0M | $157.4M | ||
| Q1 25 | $167.9M | $215.1M | ||
| Q4 24 | $180.9M | — | ||
| Q3 24 | $171.7M | $366.4M | ||
| Q2 24 | $170.6M | — |
| Q1 26 | $381.5M | — | ||
| Q4 25 | $349.5M | $529.7M | ||
| Q3 25 | $353.8M | $551.8M | ||
| Q2 25 | $321.8M | $596.1M | ||
| Q1 25 | $268.6M | $640.7M | ||
| Q4 24 | $276.1M | — | ||
| Q3 24 | $255.2M | $425.8M | ||
| Q2 24 | $309.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-69.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-15.4M | $-69.5M | ||
| Q3 25 | $-18.3M | $-70.5M | ||
| Q2 25 | $-1.3M | $-87.8M | ||
| Q1 25 | $-4.9M | $-95.2M | ||
| Q4 24 | $-2.6M | — | ||
| Q3 24 | $-3.8M | $-62.3M | ||
| Q2 24 | $-21.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-37.2M | — | ||
| Q3 25 | $-20.0M | — | ||
| Q2 25 | $-2.2M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | $-4.3M | — | ||
| Q2 24 | $-22.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | -59.8% | — | ||
| Q3 25 | -50.7% | — | ||
| Q2 25 | -6.3% | — | ||
| Q1 25 | -16.6% | — | ||
| Q4 24 | -13.3% | — | ||
| Q3 24 | -15.4% | — | ||
| Q2 24 | -81.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 35.0% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 1.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OUST
| Product revenue | $48.2M | 99% |
| Royalties | $347.0K | 1% |
SNDX
Segment breakdown not available.
